Allena Pharmaceuticals, Inc. (ALNA) Financial Analysis & Valuation | Quarter Chart
Allena Pharmaceuticals, Inc. (ALNA)
ALNAPrice: $0.07
Fair Value: 🔒
🔒score
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for pati... more
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes o... more
Description
Shares
| Market Cap | $0 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Louis Brenner |
| IPO Date | 2017-11-02 | CAGR | — |
| Employees | 12 | Website | www.allenapharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ALNA chart loading...
Fundamentals
Technicals
| Enterprise Value | $13.01M | P/E Ratio | — |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 0.13 |
| P/CF Ratio | -0.05 | P/FCF Ratio | — |
| EPS | $-0.64 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -1.61% | ROA | -0.96% |
| ROCE | -1.69% | Current Ratio | 2.11 |
| Quick Ratio | 2.11 | Cash Ratio | 1.91 |
| Debt/Equity | 0.03 | Interest Coverage | -63.4 |
| Altman Z Score | — | Piotroski Score | — |